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 Antitrypanosomal active natural
products may trigger endocrine dis-
regulation.
 Only few antitrypanosomal active
natural products sustain drug–drug
interactions.
 More complex toxic endpoints may
be elucidated by molecular simula-
tions.
 The VirtualToxLab allows identifying
side effects and associated molecular
mechanisms.
 The VirtualToxLab is freely available
for academic and non-proﬁt orga-
nizations.
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A B S T R A C T
The VirtualToxLab is an in silico technology for estimating the toxic potential – endocrine and metabolic
disruption, as well as aspects of carcinogenicity and cardiotoxicity – of drugs, chemicals and natural
products. The technology is based on an automated protocol that simulates and quantiﬁes the binding of
small molecules towards a series of currently 16 proteins, known or suspected to trigger adverse effects.
The simulations are conducted at the atomic level and explicitly allow for a mechanistic interpretation of
the results (in real-time 3D/4D), thereby complying with the Setubal principles put forward in 2002 for
computational approaches to toxicology. Moreover, the underlying “ab-initio” protocol is independent
from any training data and makes the approach universal with respect to the applicability domain. The
VirtualToxLab runs in client–server mode and is freely available to academic and non-proﬁt organizations.
As the underlying technology yields a thermodynamic estimate of the binding afﬁnity, the associated
ligand–protein complexes have been challenged by molecular-dynamics simulations to probe their
kinetic stability.
Human African trypanosomiasis is a neglected tropical disease caused by two subspecies of
Trypanosoma brucei. The control of this parasitic infection relies on a few chemotherapeutic agents, most
of which were discovered decades ago and pose many challenges including adverse side effects, poor
efﬁcacy, and the occurrence of drug resistances. Natural products, on the other hand, offer a high
potential for the discovery of new drug leads due to their chemical diversity. In this in silico study, we
analyze a series of 89 natural products and derivatives displaying anti-trypanosomal activity for their
potential to trigger adverse effects. Our results indicate a moderate potential for a number of those
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30 Z. Hu et al. / Toxicology Letters 252 (2016) 29–41compounds to bind to nuclear receptors and thereby ease the development of endocrine disregulation. A
few others would seem to inhibit enzymes of the cytochrome P450 family and, hence, sustain drug–drug
interactions.
ã 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In silico techniques for the prediction of toxicological endpoints
are extremely attractive because they are typically fast, inexpen-
sive and can be applied to both existing and hypothetical
compounds. Concepts in computational toxicology may be
classiﬁed into expert systems, QSAR (quantitative structure–
activity relationships), protein modeling and ADME (adsorption,
distribution, metabolism, excretion) modeling. A large body of
both review and research articles exists for these technologies (see,
for example, Piclin et al., 2006; Amini et al., 2007; Aronov et al.,
2007; Bender et al., 2007; Custer et al., 2007; Ecker and Chiba,
2007; Ekins, 2007; Seraﬁmova et al., 2007; Enoch et al., 2008;
Kavlock et al., 2008; Merlot, 2008; Pavan and Worth, 2008;
Benfenati et al., 2009; Green and Naven, 2009; Nigsch et al., 2009;
Spreaﬁco et al., 2009; Valerio, 2009; Rossato et al., 2010; Cronin
and Madden, 2010; Bars et al., 2011; Vuorinen et al., 2013; Gupta
et al., 2013; Roncaglioni et al., 2013; Shah and Greene, 2014;
Toropov et al., 2014; Schilter et al., 2014; Singh and Gupta, 2014;
Ekins, 2014; Vedani et al., 2015; Benfenati, 2016).
Developing and validating a three-dimensional model is
laborious but would seem to be necessary when the molecular
mechanism triggering the adverse or toxic effect occurs via a
multifaceted mode of action at the molecular level. Manifestations
of toxicity are frequently mediated by regulatory macromolecules
such as enzymes, receptors, ion channels or DNA. These targets
represent complex and ﬂexible three-dimensional entities that
attempt to optimize their interaction with a small molecule (both
natural compounds and xenobiotics) by adapting their 3D
conformation, a mechanism referred to as “induced ﬁt”. Protein-
bound solvent molecules are frequently involved in stabilizing
small-molecule ligands or, upon release to the bulk solvent
contribute favorably to the binding entropy. Accounting and
quantifying these effects belongs to the most challenging tasks in
the computational biosciences.
The VirtualToxLab (cf. http://www.virtualtoxlab.org) is an in
silico concept for estimating the toxic potential – endocrine and
metabolic disruption, aspects of carcinogenicity and cardiotoxicity
– of drugs, chemicals and natural products (Vedani et al., 2012,
2015). The technology is based on an automated protocol that
simulates and quantiﬁes the binding of small molecules (50 <
MW < 1500) towards a series of currently 16 proteins, known or
suspected to trigger adverse effects: 10 nuclear receptors (andro-
gen, estrogen a, estrogen b, glucocorticoid, liver X, mineralocorti-
coid, peroxisome proliferator-activated receptor g, progesterone,
thyroid a, thyroid b), four members of the cytochrome
P450 enzyme family (1A2, 2C9, 2D6, 3A4), a cytosolic transcription
factor (aryl hydrocarbon receptor) and a potassium ion channel
(hERG). The simulations are conducted at the atomic level and
explicitly allow for a mechanistic interpretation of the results in
real-time 3D/4D, thereby complying with the Setubal principles
put forward in 2002 (Worth and Cronin, 2004) for computational
approaches to toxicology. Moreover, the underlying “ab-initio”
protocol is independent from any training data and makes the
approach universal with respect to the applicability domain. The
toxic potential of a compound – its ability to trigger adverse effects
– is derived from its computed binding afﬁnities toward these very
proteins. The computationally demanding simulations are per-
formed in client–server mode on a Linux cluster at the University ofBasel. The graphical-user interface allows building and uploading
molecular structures, inspecting and downloading the results and,
most important, rationalizing any prediction at the atomic level by
interactively analyzing the binding mode of a compound with its
target protein(s) in real-time 3D/4D. Access to the VirtualToxLab is
available free of charge for academic institutions, public hospitals,
governmental agencies, regulatory bodies and non-proﬁt orga-
nizations (cf. http://www.biograf.ch/data/projects/OpenVirtual-
ToxLab.php).
Molecular Dynamics (MD) simulations allow for analyzing and
quantifying the interaction of a small molecule bound to a protein
over an – albeit moderate – time span of typically a few nanoseconds
to one microsecond. This is performed by applying Newton’s law of
motiontoeach atomof thesolvatedligand–proteincomplexexposed
to the forces acting on it through its molecular environment. Those
forces are governed byan appropriate force ﬁeld and allowance must
be given for both structural and bulk solvent (typically water). A
wealth of literature exists on both theory and application of MD
simulations (see, for example, Mortier et al., 2015; Zhao and
Caﬂiesch, 2015; Kerrigan, 2013). In our context, we analyze the
stability of salt bridges and hydrogen bonds, the presence or absence
of distinguished lipophilic interactions as well as the role of bound
solvent. For the simulation and quantiﬁcation (of the structural
prerequisites) of adverse or toxic effects triggered by molecular
mechanisms, MD simulations would seem to be the tool of choice to
conﬁrm (or refute) the ﬁndings obtained by thermodynamic
approaches (e.g. the VirtualToxLab).
Human African trypanosomiasis (HAT) is a neglected tropical
disease caused by two subspecies of Trypanosoma brucei (De
Olivera et al., 2015). The associated infection is life threatening and
represents a risk to large parts of the populations in poor tropical
countries. The control of this parasitic infection relies on a few
chemotherapeutic agents, most of which were discovered decades
ago and pose many challenges due to adverse side effects, long
treatment cycles, poor efﬁcacy, high costs, the occurrence of drug
resistances, and limited availability (Orhan et al., 2010; Hotez et al.,
2007). Therefore, the discovery of novel, safe, and effective
antiprotozoal agents remains an urgent need. Natural products
play a signiﬁcant role in the discovery of new drug leads because of
the unmatched availability of chemical diversity (Kellenberger
et al., 2011). Considering the severe disadvantages of existing
drugs, there is a clear and pressing need for the development of
safer and more effective drugs for the treatment of HAT. Many
natural products have been reported showing antitrypanosomal
activity—including ﬂavonoids, xanthones, lignans, terpenes, and
alkaloids. We recently identiﬁed several classes of natural products
with promising in vitro antitrypanosomal activity (Kellenberger
et al., 2011; Hata et al., 2011; Farimani et al., 2011; Julian et al., 2011;
S’lusarczyk et al., 2011; Zimmermann et al., 2014; Ayyari et al.,
2014; Usuki et al., 2014). These compounds represent a diverse and
challenging series of chemicals for in silico proﬁling with respect to
adverse effects.
2. Methods
2.1. The VirtualToxLab
The technology underlying the VirtualToxLab has been recently
described in detail in this journal (Vedani et al., 2015, 2012) and
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based on a client–server protocol and consists of a graphical user
interface (uploading compounds, downloading and visualizing
results) and the server backend (1024-node Linux cluster where
the calculations are performed). The user interface features a 3D
model builder for readily generating the three-dimensional
structure of any small molecule of interest, an embedded 3D
viewer for inspecting the compounds to be uploaded and a 3D/4D
viewer for analyzing the output structures (protein–ligand
complexes). In a ﬁrst step, a compound’s conﬁgurations (position,
orientation, conformation) in aqueous solution are sampled and
quantiﬁed using the Aquarius software (Vedani et al., 2015; Fig. 1,
left). Then, a similar protocol with allowance for induced ﬁt is
employed at the protein (Fig. 1, center) using Alignator (template-
based alignment: Smieško, 2013) and Cheetah (Monte-Carlo
sampling, dynamic solvation, reﬁnement: Vedani et al., 2015;
Rossato et al., 2010). In a next step, the change in free energy DG of
the small molecule when binding from the aqueous environment
to the protein is estimated (BzScore4D: Vedani et al., 2015).
Finally, the afﬁnities towards all 16 target proteins are weighted
and compiled into a single ﬁgure: the toxic potential ranging from
0.0 (benign) to 1.0 (extreme). Based on its value (low, intermediate,
high), different follow-up procedures — including MD, PP, ADMET
and consensus scoring — are then performed. For details, see
Vedani (2016: Fig. 15).
The technology has been extensively validated (cf. Vedani et al.,
2015, 2012 and references cited therein). The predictive power of
the current version and that of the 16 individual targets are
available on-line (Biographics Laboratory 3R, 2016a; Vedani, 2016:
Fig. 6, respectively).
2.2. Molecular-dynamics (MD) simulations
The MD simulations were carried out in consensus mode using
(i) AMBER12 (Case et al., 2012) employing the AMBER FF14sb force
ﬁeld (Case et al., 2014), (ii) NAMD2.9 (Phillips et al., 2005)
combined with the CHARMM36 force ﬁeld (Best et al., 2012) and
(iii) Desmond (Darden et al., 1993) along with MacroModel
(Mohamadi et al., 1990) featuring the OPLS2005 force ﬁeld (Banks
et al., 2005). The details of the individual protocols are given in the
Supplementary data (File: MolecularDynamics.pdf). The need to
augment the VirtualToxLab calculations by MD simulations arises
from the fact that the Monte-Carlo sampling technology employed
in the VirtualToxLab (software Cheetah, cf. Vedani et al., 2015;
Rossato et al., 2010) computes a thermodynamic value for a
compound’s strength to bind to a given target protein. While this isFig. 1. 4D-Boltzmann sampling as employed in the VirtualToxLab. Left: a compound’s (her
Center: sampling and quantifying the ligand’s representations at the binding site of t
54 identiﬁed) conformations in aqueous solution and 6 (out of 24 identiﬁed) at the protein
structure of Alisol A.a necessary condition for binding, it is not sufﬁcient as the ligand–
protein interaction must be stable over a reasonable period of time
in order to trigger an (e.g. agonistic) effect. This kinetic aspect – i.e.
the time-dependent stability of a ligand–protein complex – can be
assessed reasonably well through MD simulations. The time span
for which a MD simulation should be conducted is debatable; in
this study we used a reasonable span time of 108 s (10 ns), which
allows to safely monitor the stability of key ligand–protein
interactions (e.g. hydrogen bonds) as well as the response of the
protein to ligand binding (induced ﬁt).
2.3. Antitrypanosomal compounds
The 3D structures of the employed 89 natural antitrypanosomal
compounds (Farimani et al., 2011; Julian et al., 2011; S’lusarczyk
et al., 2011; Ayyari et al., 2014) were generated with BioX (Dobler,
2014) and optimized using the directional Yeti force ﬁeld (Vedani
and Huhta, 1990). As part of the VirtualToxLab protocol, their
conformations were exhaustively sampled in aqueous solution
(Vedani et al., 2015). Their chemical structures along with the
SMILES codes are given in the Supplementary data (File:
Compounds.pdf). The most feasible protonation state at physio-
logical pH (7.4) is determined by the VirtualToxLab (Vedani et al.,
2015). The conformational variability of the compounds was
assessed by exhaustive conformational sampling in aqueous
solution (software MacroModel: Mohamadi et al., 1990); details
of the underlying protocols are given in (Vedani et al., 2015, 2012).
3. Results and discussion
The results with the VirtualToxLab were obtained with version
5.5 (September 2015). Simulation of the binding of the 89 com-
pounds (natural products and some derivatives) to the 16 target
proteins and estimating their toxic potential required a total
6189 CPU (central processing unit) hours. Individual binding
afﬁnities and the toxic potential are shown graphically in
Figs. 2 and 3, summarized in Table 1 and are given in detail in
the Supplementary data (File: VirtualToxLab.xlsx).
The more frequently identiﬁed target proteins of the anti-
trypanosomal compounds include the androgen, estrogen a,
estrogen b, glucocorticoid and aryl hydrocarbon receptor. Only
rarely was binding to the enzymes of the cytochromes P450 family
(as inhibitors), the Liver-X and the PPARg observed and occasional
binding to the remaining targets identiﬁed. Table 1 summarizes
the binding of the most interesting ﬁndings (for details, cf.
Supplementary data). For all compounds with a calculated bindinge: Alisol A, one of the investigated compounds) representations in aqueous solution.
he target protein (here: the glucocorticoid receptor). For clarity, only 12 (out of
 are shown. The images were generated with the BioX software (Dobler, 2014). Right:
Fig. 2. Toxic potential and binding afﬁnities as obtained by the VirtualToxLab (and shown by the molecule panel in the graphical-user interface). The selection (sorted by the
toxic potential) shows both values intensity-colored, i.e. the darker (toxic potential = red, afﬁnities = blue) the more prominent the effect. Upon moving the computer mouse
over an afﬁnity ﬁeld, the underlying numerical value is displayed (Vedani et al., 2015). A white ﬁeld indicates “no binding”, i.e. a computed binding afﬁnity > 100 mM. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
1 Among the 12 identiﬁed poses, only one ﬁnds the phenolic hydroxyl O atom in
the vicinity of Arg752—however, at an O  H distance of 4.8 Å, far too distant for a
substantial stabilization. Consequently, that pose is computed to contribute a mere
2.8  105 to the Boltzmann ensemble. Nonetheless, we run a MD simulation
starting from that very pose, testing whether the equilibration protocol might ﬁnd a
stronger interaction with Arg752—without success, though: a strong interaction of
the hydroxyl O atom of 97 with Arg752 is only present for less than 4% of the time. At
that time, the two other hydrogen bonds are signiﬁcantly weakened. Throughout
the entire simulation, the total protein–ligand interaction energy remains 10%
weaker than that for the main pose.
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(Hu, 2015) to probe the kinetic stability of the underlying ligand–
protein complex. For the more interesting thereof, MD simulations
were performed in consensus mode (AMBER, CHARMM and
Desmond, respectively). The details are given in the Supplementary
data (File: MolecularDynamics.pdf). The toxic potential is comput-
ed from the individual binding afﬁnities towards the 16 off-targets
(for details, see Vedani et al., 2015; Vedani, 2016) currently
included in the VirtualToxLab. It should be interpreted as an alert,
indicating a compound’s (thermodynamic) probability to trigger
adverse effects. Fig. 3 (top) shows the values obtained for the
89 compounds in a pictorial way. The computed values range from
0.161 (benign) to 0.593 (potentially harmful). The distribution of
this value for the natural compounds with antitrypanosomal
activity indicates a moderate risk with respect of triggering
adverse effects, particularly at continued exposure.
3.1. Endocrine disruption—binding to nuclear receptors
Endocrine disruption could be triggered by binding to one or
several of the 10 nuclear receptors (AR, ERa, ERb, GR, LXR, MR,
PPARg, PR, TRa, TRb) currently tested for in the VirtualToxLab.
Typical ligands – e.g. 17b-estradiol, bisphenol A or diethylstilbes-
trol – feature a lipophilic core augmented by polar ends.
Nonetheless, compounds with only one polar end (e.g. substituted
phenols or phtalates) are also known to bind to these entities—
albeit with a smaller afﬁnity. Among the investigated 89 anti-
trypanosomal compounds, 22 show a favorable interaction with
one of the nuclear receptors, i.e. leading to a computed binding
afﬁnity < 100 nM (cf. Fig. 3: bottom). However, not all of these
ligand–protein complexes are kinetically stable when probed by
means of MD simulations (cf. below). Concerning the computed
binding afﬁnity, the interaction of 97 with the androgen receptor
(Table 1 and Fig. 4) is the most noticeable. According to our
simulations, the paprazine derivative engages in strong inter-
actions with two key amino-acid residues of the receptor
(Asn705 and Thr877). However, it cannot reach out (bind) to
Arg752, which would be necessary for triggering an agonistic
effect. Instead, it engages in a hydrogen bond with the backbone
amide-H atom of Met787. Therefore, 97 might act as an antagonist
(antiandrogen), which is not desirable either. The computed
binding afﬁnity is 8.4 nM, which underlines the strength of the
interaction. Fig. 4 shows the thermodynamic binding mode – i.e.
the energetically most favorable pose – of 97 (left) and its kinetic
stability during a 10 ns MD simulation. The interactions with
Asn705 and Thr877 remain stable throughout the entiresimulation while the desired one with Arg752 is never truly
established.1 The total energy (of the simulation employing the
main pose; blue curve) shows only small ﬂuctuations compared
with the initial state (corresponding to the thermodynamically
most favorable binding mode as identiﬁed by the VirtualToxLab).
Other compounds and targets include 98 binding to the estrogen
receptor a and the mineralocorticoid receptor, 88 to the
glucocorticoid receptor and 33 to the progesterone receptor
(Fig. 5). Concerning 98, it should be noted that it binds to both
entities in a cis conﬁguration, while the energetically more
favorable mode is trans. A cis ! trans interconversion in situ might
be feasible but is not very probable. The binding of 33 to the
progesterone receptor would seem to be of interest as the molecule
is stabilized by two hydrogen bonds with Thr894 and Arg766,
respectively. Compound 88 at the glucocorticoid receptor is
stabilized by three hydrogen bonds with Gln670 and Arg611 and
Asn564, respectively.
3.2. Cardiotoxicity—binding to the hERG ion channel
Of great interest would be to know if natural antitrypanosomal
compounds might inhibit the hERG ion channel and thereby
triggering cardiotoxic (arrhythmic) effects. Some of the investigat-
ed compounds would, indeed, seem to have a potential for binding
to hERG—for example 47 for which an appreciable afﬁnity of
119 nM is calculated. Fig. 6 shows the details of its proposed
binding to hERG. The ammonium group (pKa,calc = 9.45, hence,
protonated at physiological pH) engages in two hydrogen bonds
with Ser61 and Ser167, respectively. The lactone carbonyl O atom
forms a hydrogen bond with Tyr295 and the hydrophobic portions
of the molecule are embedded in lipophilic parts of the binding
pocket. As for the hERG ion channel no experimental (X-ray or
NMR) 3D structure is currently available, a homology model for
this protein is used instead (cf. Vedani, 2016: Table 2). Therefore,
any conclusion drawn therefrom should be interpreted with care.
Fig. 3. Top: bandwidth of the toxic potential of the 89 antitrypanosomal compounds. Bottom: distribution of individual binding afﬁnities over the 16 target proteins as
obtained by the VirtualToxLab. For clarity, only afﬁnities < 100 mM are depicted. The numbers on the horizontal axis correspond to the compound IDs. White spots on the ﬂoor
indicate that the compound(s) display(s) no activity towards the target(s). The 3D plot and the underlying data are available in the Supplementary data in original Excel
formatting.
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Table 1
Four selected compounds and their suspected protein targets as identiﬁed by the VirtualToxLab.
ID Structure Main targeta
Afﬁnityb Toxic
potentialc
Ligand–protein interactions (VirtualToxLab):
Thermodynamic binding mode, i.e.
energetically most favorable pose
10 ns MD simulationsd (AMBER, CHARMM): Kinetic binding mode
33 Progesterone
receptor:
10.1 nM 0.593
Not supportive: Hydrogen bonds with Thr894 and Arg766 are only
present during 1% and 2% of the simulation time, respectively (see
also Fig. 5)
37 Estrogen
receptor b:
20.4 nM 0.560
Partially supportive: Salt bridge (with the ammonium H atoms)
with Glu305 is present during 92% and 17% of the simulation time,
respectively. The nearby Arg346 forms a salt bridge with Glu305 (as
observed in the native state) for less than 5% of the time only
54 Aryl
hydrocarbon
receptor:
46.0 nM 0.523
Partially supportive: The hydrogen bond with Ser82 is present
during 54% of the simulation time (cf. Fig. 7)
97 Androgen
receptor:
12.7 nM 0.555
Fully supportive: Hydrogen bonds with Asn705 and Thr877/
Ser753 are present during 96% and 66% of the simulation time,
respectively (cf. Fig. 4)
a Of the 16 tested proteins: AhR, AR, ERab, GR, hERG, LXR, MR, PPARg, PR, TRab, 1A2, 2C9, 2D6, 3A4.
b Calculated by 4D Boltzmann scoring (Vedani et al., 2015; see also Fig. 12).
c Expected effects: TP < 0.3: no, 0.3 < TP < 0.5: weak, 0.5 < TP < 0.6: moderate, 0.6 < TP < 0.7: strong, TP > 0.7 extreme.
d MD is supportive, if the stabilizing hydrogen-bond interaction(s) are present throughout the entire simulation.
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Fig. 4. Left: binding of 97 to the androgen receptor. The ligand and key amino-acid residues are shown in licorice, the protein is depicted by its inner surface (colored by z-
depth). Hydrogen bonds are indicated as yellow dashed lines. The image was generated employing the VMD software (Humphrey et al., 1996). Center: 10.0 ns MD simulation
indicating the stable character of the ligand–protein interactions throughout the entire simulation. Right: structure of 97. (For interpretation of the references to colour in this
ﬁgure legend, the reader is referred to the web version of this article.)
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Ser164, Ser267) share hydrogen bonds with the ammonium group,
while the VirtualToxLab (Monte-Carlo sampling) sticks with
Ser61 and Ser164 at the lowest-energy pose. In the VirtualToxLab
(4D representation), the serine triple is also observed, of course
only in pairs at the time. This represents an agreement of the
VirtualToxLab and the MD simulation and – in this case – of
thermodynamic and kinetic approaches.Fig. 5. Top panel: binding of 98 to the estrogen receptor a (left) and to the mineralocortic
and 33 to the progesterone receptor (right). The ligand and a key amino-acid residue are
ﬁlling spheres, the protein is depicted by its inner surface (colored by z-depth) and str
dashed lines. The image was generated employing the VMD software (Humphrey et al
references to colour in this ﬁgure legend, the reader is referred to the web version of t3.3. Carcinogenicity—binding to the aryl hydrocarbon receptor
A few compounds of the series might bind to the Aryl
hydrocarbon receptor and, thereby, trigger mechanisms eventually
leading to carcinogenic effects. An example is tanshinone, which is
computed to bind with an afﬁnity of 46 nM to this target. This is
shown in Fig. 7: the aromatic and aliphatic portions of the molecule
are accommodated by lipophilic amino-acid residues of theoid receptor (right). Bottom panel: binding of 88 to the glucocorticoid receptor (left)
 shown in licorice, hydrophobic residues lining the binding pocket as yellow space-
uctural water molecules by blue spheres. Hydrogen bonds are indicated as yellow
., 1996). Right of the color plates: respective structures. (For interpretation of the
his article.)
Fig. 6. Left: binding of 47 to the hERG ion channel. The ligand and key amino-acid residues are shown in licorice, the protein is depicted by its inner surface (colored by z-
depth). Hydrogen bonds are indicated as yellow dashed lines. The image was generated employing the VMD software (Humphrey et al., 1996). Center: 10.0 ns MD simulation
indicating the somewhat labile character of the ligand–protein interactions—particularly of the 47  Ser61 hydrogen bond. Right: structure of 47. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 7. Left: binding of 54 (tanshinone) to the Aryl hydrocarbon receptor. The ligand and a key amino-acid residue are shown in licorice, hydrophobic residues lining the
binding pocket as yellow space-ﬁlling spheres, the protein is depicted by its inner surface (colored by z-depth). The hydrogen bond is indicated as a yellow dashed line. The
image was generated employing the VMD software (Humphrey et al., 1996). Center: 10.0 ns MD simulation indicating the somewhat labile kinetic character of the ligand–
protein interactions. Right: structure of 54. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
36 Z. Hu et al. / Toxicology Letters 252 (2016) 29–41protein, and one carbonyl O atom engages in a hydrogen bond with
Ser82 which remains present during 54% of the MD simulation (cf.
Table 1). As for hERG, no experimental structure exists for the Aryl
hydrocarbon receptor and a homology model is used instead (cf.
Vedani, 2016: Table 2). Again, any conclusion drawn therefrom
should therefore be interpreted with care. Nonetheless, the quite
lipophilic (log P = 2.8—cf. Table 2) and planar compound is
reasonably suited to bind to the Aryl hydrocarbon receptor from
a structural point of view.Table 2
Physico-chemical properties of selected compounds employed in this study. Preferred v
metabolite of 37 (cf. Fig. 10).
Compound MW (g/mol) log P log S 
33 333 0.7 1.0 
37 386 3.6 4.3 
44 460 3.6 4.4 
47 400 4.0 4.5 
54 294 2.8 3.7 
88 473 4.5 5.6 
97 299 2.0 3.8 
98 313 2.9 4.4 
M37 402 2.8 3.8 
Eﬂornithine 182 2.7 1.0 
MW: molecular weight {MW | 130  MW  725}.
log P: predicted octanol/water partition coefﬁcient {log P | 2.0  log P  +6.5}.
log S: predicted aqueous solubility in mol/dm3 {log S | 6.5  log S  0.5}.
Oral Abs: Predicted human oral absorption on a 0–100% scale {<25% is low, >80% is hi
Caco Perm: Predicted apparent Caco-2 cell permeability in nm/sec {<25 is poor, >500 
PSA: polar surface area {PSA | 7  PSA  200}.3.4. Metabolic disruption—binding to enzymes of the CYP450 family
Four target proteins in the VirtualToxLab belong to the family of
the cytochrome P450 enzymes (1A2, 2C9, 2D6, 3A4) and the
technology investigates whether a given compound may inhibit
these entities, thereby triggering adverse drug–drug interactions.
Our simulations indicate that a few compounds can indeed interact
with the enzymes and, particularly, bind to the catalytic FeIII ion.
Compound 88 binds moderately (0.90 mM) to CYP450 2D6 byalues are given in square brackets. For details, see ref. (Schrödinger, 2011). M37 is a
Oral Abs (%) Caco Perm (nm/s) PSA (Å2)
74 250 79
91 240 75
82 84 113
93 240 76
100 1900 57
100 1200 74
74 100 104
91 410 86
80 100 94
20 3 95
gh}.
is great}.
Fig. 8. Left: binding of 88 (as a potential inhibitor) to CYP450 2D6. The ligand, the heme and key amino-acid residues are shown in licorice, the protein is depicted by its inner
surface (colored by z-depth); the Fe3+ is shown as a green sphere. Hydrogen bonds are indicated as yellow dashed lines. The image was generated employing the VMD
software (Humphrey et al., 1996). Center: 10.0 ns MD simulation indicating the quite stable character of the ligand–protein interactions. Right: structure of 88. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Z. Hu et al. / Toxicology Letters 252 (2016) 29–41 37having its carbonyl O atom coordinated to the metal ion and its
hydroxyl groups engaging in hydrogen bonds with Gln244 and
Ser304 (Fig. 8: left). The hydrophobic portion of 88 is stabilized by
lipophilic residues lining the binding pocket (Phe120, Leu213,
Leu241 and Phe483). The 10.0 ns MD simulation indicating the
initially labile hydrogen-bond network that becomes stable during
the second part of the simulation. The interaction with the heme
remains strong throughout the entire simulation. Therefore, the
MD simulation (Fig. 8: center) supports the thermodynamic
(Monte-Carlo sampling) ﬁndings.
Compound 44 binds moderately (1.80 mM) to CYP450 3A4
(Fig. 9). Apart from the interaction of the carbonyl O atom with the
heme, a salt bridge of the protonated ammonium moiety with
Glu374 contributes strongly to the binding. This interaction
remains present throughout the entire simulation. The noticeable
gain in the ligand–protein interaction energy after approximately
1.2 ns of simulation time is caused by a slight reorientation of the
heme rings (induced ﬁt). However, a binding afﬁnity > 1 mM would
not seem to trigger too strong side effects (e.g. drug–drug
interactions), except, possibly at long exposure times.
Less problematic than inhibition of an enzyme of the
cytochrome P450 series by a compound is its metabolic modiﬁca-
tion by the enzyme. Nonetheless, it would seem to be appropriate
to investigate this mechanism. This was examined by employing
version 4.9 of the technology (Vedani et al., 2012), while the most
recent version checks for inhibition instead (Vedani et al., 2015)
and evaluated the resulting metabolites by the VirtualToxLab as
well. According to our simulations, 37 would seem to bind toFig. 9. Left: binding of 44 (as a potential inhibitor) to CYP450 3A4. The ligand, the heme a
surface (colored by z-depth); the Fe3+ is shown as a green sphere. Hydrogen bonds ar
software (Humphrey et al., 1996). Center: 10.0 ns MD simulation indicating the overall q
interpretation of the references to colour in this ﬁgure legend, the reader is referred toCYP450 2D6 and thereby position a methyl group favorably for a
nucleophilic attack (Fig. 10: left). The resulting metabolite—
hydroxylated from R-CH3 to R-CH2OH (Fig. 10: center and right,
highlighted in red) does indeed bind stronger to the glucocorticoid
receptor than the parent compound by forming an extra hydrogen
bond with Gln642 (Fig. 11). Consequently, the toxic potential of the
metabolite is higher (0.632) than that of its parent compound 37
(0.560).
3.5. Derivatives
14 of the investigated sesquiterpene lactones might trigger
undesired or unspeciﬁc activities due to their exo-methylen
functionality, which may covalently bind to biological nucleo-
philes. Therefore, this group has been chemically masked in some
compounds (33R/S,36–47). Modifying otherwise too reactive
functional groups is a typical strategy in deriving potential drug
candidates from natural scaffolds (see, for example, Barnes et al.,
2016). According to our calculations, the corresponding natural
products display only a low potential (0.178–0.316) to trigger
adverse effects. As they were not thought being investigated as
potential drug candidates, they are not discussed further here.
3.6. Chemotherapeutic agents—eﬂornithine
To compare our in silico results obtained for the 89 compounds
with clinically used antiprotozoal drugs, we have simulated
berenil, diminazene, eﬂornithine, pentamidine and suraminnd key amino-acid residues are shown in licorice, the protein is depicted by its inner
e indicated as yellow dashed lines. The image was generated employing the VMD
uite stable character of the ligand–protein interactions. Right: structure of 44. (For
 the web version of this article.)
Fig. 10. Interaction of 37 (as a potential substrate) with CYP450 2D6. The heme and 37 are shown in licorice, the iron (green) and the reactive oxygen species (red) as spheres,
respectively. The O  H distance of 2.37 Å and the O  HC angle of 128 suggest an ideal geometry for the nucleophilic attack and the formation of a hydroxylation product.
Hydrogen bonds are indicated as yellow dashed lines. The image was generated employing the VMD software (Humphrey et al., 1996). (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 11. Left: binding of a potential metabolite of 37 to the glucocorticoid receptor. The ligand and key amino-acid residues are shown in licorice, the protein is depicted by its
inner surface (colored by z-depth). Hydrogen bonds are indicated as yellow dashed lines. The image was generated employing the VMD software (Humphrey et al., 1996).
Center: 10.0 ns MD simulation indicating the quite stabile character of the ligand–protein interactions. Right: structure of the metabolite. (For interpretation of the references
to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
38 Z. Hu et al. / Toxicology Letters 252 (2016) 29–41employing identical protocols. The most interesting compound
with respect to adverse effects (as tested for in the VirtualToxLab) is
eﬂornithine, which would seem primarily bind to the Liver-X
receptor at a computed afﬁnity of 410 nM but also – albeit at a
lower afﬁnities – to the glucocorticoid receptor (1.0 mM), the
estrogen receptor a (3.7 mM) and b (2.6 mM), the progesterone
receptor (3.6 mM) and the mineralocorticoid receptor (68 mM).
This represents a quite interesting bandwidth of potential target
proteins might explain some of its side effects, which would seemFig. 12. Left: binding of eﬂornithine to the Liver-X receptor. The ligand and key amino-ac
yellow space-ﬁlling spheres, the protein is depicted by its inner surface (colored by z-dep
employing the VMD software (Humphrey et al., 1996). Center: 10.0 ns MD simulation indi
of eﬂornithine. Please note that at physiological pH only the terminal amine group is pr
deprotonated (pKa,calc = 3.1). (For interpretation of the references to colour in this ﬁgurto be more important than the computed overall toxic potential of
moderate 0.412. However, those targets would not seem to be
directly associated with the reported side effects triggered by
eﬂornithine (Cook, 1995). Fig. 12 (left) shows the interactions of
eﬂornithine with the Liver-X receptor in detail. The molecule is
primarily stabilized by two salt bridges with Arg319 and Glu281,
but also through a hydrogen bond with Ser278. The lipophilic part
of eﬂornithine is accommodated by Leu274, Ile277 and Leu330,
respectively, lining the lower part of the binding pocket. Fig. 12id residues are shown in licorice, hydrophobic residues lining the binding pocket as
th). Hydrogen bonds are indicated as yellow dashed lines. The image was generated
cating the quite stabile character of the ligand–protein interactions. Right: structure
otonated (pKa,calc = 6.9 and 10.1, respectively) while the carboxyl group is certainly
e legend, the reader is referred to the web version of this article.)
Table 3
Consensus scoring employing ToxTree (Joint Research Centre, 2010a), MolInspiration
(Molinspiration, 2012a), and Lazar (Helma, 2010). M37 is a metabolite of 37 (cf.
Fig. 10).
Compound ToxTree MI/NRL MI/ICM MI/PI MI/EI Laz/Car Laz/Mut
33 ++ 0.37 0.24 0.01 0.28 0 0
37 ++ 0.05 0.16 0.04 0.28 0 0
44 ++ 0.03 0.01 0.16 0.29 1 0
47 ++ 0.01 0.08 0.13 0.09 0 0
54 ++ 0.45 0.06 0.63 0.22 2 0
88  0.81 0.10 0.19 0.64 2 0
97 ++ 0.12 0.02 0.01 0.08 2 0
98 ++ 0.05 0.06 0.05 0.02 2 0
M37 ++ 0.12 0.21 0.08 0.34 0 0
Eﬂornithine ++ 0.73 0.19 0.14 0.08 1 0
ToxTree: General harmfulness — low (), intermediate (+), high (++).
MI/NRL: MolInspiration—probability to bind to a nuclear receptor {range |
1.0  range  +1.0}.
MI/ICM: MolInspiration—probability to modulate an ion channel {range | 1.0 
range  +1.0}.
MI/PI: MolInspiration—probability to inhibit a protease {range | 1.0  range  +1.0}.
MI/EI: MolInspiration—probability to inhibit an enzyme {range | 1.0  range
 +1.0}.
Laz/Car: Lazar—carcinogenicity {six tests: range | 0  range  6}.
Laz/Mut: Lazar—mutagenicity {two tests: range | 0  range  2}.
Z. Hu et al. / Toxicology Letters 252 (2016) 29–41 39(center) shows the molecular-dynamical behavior of the com-
pound. While the salt bridge with Arg319 remains stable
throughout the entire simulation, the interaction with
Glu281 weakens somewhat after approximately 7 ns of simulation
time, leading to a moderate overall attenuation of the binding.
3.7. Physico–chemical properties—bioavailability of compounds
Computational assessment of a compound’s toxicity should
always be discussed along with its ADME properties as those deﬁne
the bioavailability—a prerequisite for triggering a molecular
mechanism leading a toxic effect (Vedani et al., 2015, 2012). To
assess the physico–chemical properties of the antitrypanosomal
compounds, we employed the QikProp software (Schrödinger,
2011) accessible through the VirtualDesignLab (Eid et al., 2013).
Table 2 shows the key parameters for the compounds discussed in
this account. From the point of view of the (computed) solubility,
bioavailability, and cell permeability, all compounds would seem
to be present at appreciable concentrations in the systemic
circulation to trigger the adverse effects discussed above.
Interestingly, eﬂornithrine displays quite opposite values than
the natural compounds, i.e. a low lipophilicity and a high solubility
combined with a low bioavailability and a poor membrane
permeability.
3.8. Consensus scoring—challenging the VirtualToxLab
Although the VirtualToxLab employs a sophisticated protocol to
assess a compound’s toxic potential, both false-positive and false-
negative results may occur. False-negative results are more
frequent as the technology “only” tests 16 pathways that may
eventually manifest a toxic response while many more adverse
mechanisms exist (Vedani et al., 2015). Another source for
underestimating a compound’s harmful character is associated
with the fact that exhaustive sampling of ligand binding to a
macromolecule is not possible at the currently available computing
power, i.e. the correct binding mode might not have been
identiﬁed, particularly for large and very ﬂexible molecules. The
total computing time for the 89 tested compounds amounted to
6189 CPU hours on a Linux cluster (5.2 days of wall-clock time as
the longest individual simulation required 125 CPU hours).
Exhaustive sampling would imply a 40–80 times longer protocol,
which is currently not feasible. Even then, it could not be
guaranteed that the correct binding was identiﬁed, as induced
ﬁt – adaptation of the protein conformation to the ligand’s
topology – might still not be properly addressed. False-positive
results may occur when underestimating a compound’s desolva-
tion energy, which, in turn, leads to too high binding afﬁnities or by
a structural feasible binding mode that is not retained (stable)
throughout a molecular-dynamics simulation.
For an alternative assessment of our compound’s harmful
character, we have employed three pieces of third-party software:
Toxtree (Joint Research Centre, 2010a) based on the Cramer rules
(Joint Research Centre, 2010b), MolInspiration (Molinspiration,
2012a) based on a molecular-fragment database (Molinspiration,
2012b) and Lazar (Helma, 2010), using structure–activity relation-
ships (Helma, 2006). The results for the compounds discussed
above are given in Table 3.
The ToxTree results would seem to be somewhat surprising but
they are based on rather simple rules (Joint Research Centre,
2010b), e.g. the occurrence of more than one aromatic ring, the
presence of a substituted aromatic ring or any atom other then C, H,
O, N or divalent S. If more than two of these conditions are met, a
high probability (denoted “++” in Table 3) results. In MolInspiration,
the most interesting quantity is the probability to bind to a nuclear
receptor, which is indeed high for some of the compounds (54, 88and, to a lesser extent, 97), which is in agreement with our ﬁndings.
Unfortunately, the binding of 47 to hERG as identiﬁed by the
VirtualToxLab is not conformed by MolInspiration, where even a
slightly negative probability is calculated. This might be due to the
fact, that only heavy but no H atoms are considered in the
technology. Protonated N moieties are typical features of hERG
blockers—astemizole and cisapride, for example, which are
calculated at negative probabilities of 0.06 and 0.15, respectively.
Concerning Lazar, the six carcinogenicity tests are of particular
interest, as the VirtualToxLab tests for binding to the aryl
hydrocarbon receptor, which is associated with a carcinogenic
mechanism. Here, consensus exists on 54, which is computed to
bind at 46 nM to this target. 88, 89 and 98 also alerted by Lazar bind
only in the mM range to the aryl hydrocarbon receptor. Again,
eﬂornithrine displays quite different properties than most natural
compounds, e.g. a modest probability to bind to ion channels and
proteases but much less to nuclear receptors. The latter is in
disagreement with the results from our structure-based simu-
lations. However, it is unknown, if and how the zwitter-ionic state
of the molecule is taken into consideration by these approaches. In
all VirtualToxLab and subsequent MD simulations, the protonation
state at physiological pH (7.4) was employed (cf. Fig. 12: right).
In summary, our studies do not associate a high toxic potential –
endocrine and metabolic disruption, as well as aspects of
carcinogenicity and cardiotoxicity – to the investigated 89 natural
compounds and derivatives with antitrypanosomal activity and
neither do (with exception of ToxTree) the other employed software
tools. Of course, adverse effects might be triggered via a wealth of
mechanisms, only a few of which have been simulated in this
study. As natural products, in contrast to classic synthetic drugs,
often feature a complex topology decorated with a larger number
of hydrogen-bond functionalities, it is less likely that they meet
another (off-) targets binding pattern than rather simple chemo-
therapeutic compounds, e.g. the antitrypanosomal small-molecule
drug diminazene. On the other hand, the unique conﬁguration of
natural compounds might privilege them to trigger more complex
agonistic mechanisms.
4. Conclusions
To investigate potential side effects triggered by antitrypano-
somal natural products and derivatives, we combined the
40 Z. Hu et al. / Toxicology Letters 252 (2016) 29–41VirtualToxLab (simulation and quantiﬁcation of small-molecule
binding to nuclear receptors, enzymes of the CYP450 family, the
Aryl hydrocarbon receptor and the hERG ion channel) and
molecular-dynamics simulations in consensus mode (three
different pieces of software). While the former addresses
“thermodynamic” binding, the latter probe the kinetic stability
of ligand–protein complexes. Among the 89 tested compounds, we
identiﬁed a paprazine derivative to bind strongly and kinetically
stable to the androgen receptor, thereby possibly leading to
endocrine disruption. One other compound each would seem to
interact with the aryl hydrocarbon receptor and hERG, respectively.
With one exception, the investigated metabolites are not expected
to trigger stronger effects than their parent compounds. Finally, we
compared our results with those obtained by third-party software
aimed at estimating adverse effects. In summary, the investigated
compounds would not seem to represent an immediate health risk
but a few of them might, at longer exposure, trigger undesirable
effects. From computational studies, highly decorated complex
molecular topologies of natural compounds would seem to be less
prone to trigger adverse effects than simpler chemical structures
(as employed in classic therapies) which may easier bind to
undesired off-targets (see, for example Biographics Laboratory 3R,
2016b: results on 2666 tested compounds as well as Ekins, 2014;
Roberts, 2010).
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